<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD08820000_2</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q08881</UniProt_ID>
  <Seq_Length>620</Seq_Length>
  <Molecule_Weight>71831</Molecule_Weight>
  <KEGG_ID>hsa:3702</KEGG_ID>
  <Orthology_ID>K07363</Orthology_ID>
  <EBI_ID>EBI-968552</EBI_ID>
  <Function_Summary>Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF00779:BTK@@PF00169:PH@@PF07714:Pkinase_Tyr@@PF00017:SH2@@PF00018:SH3_1</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>5</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Kinase EMT</Alias>
      <Alias>T-cell-specific kinase</Alias>
      <Alias>Tyrosine-protein kinase Lyk</Alias>
      <Alias>IL-2-inducible T-cell kinase</Alias>
      <Alias>Interleukin-2-inducible T-cell kinase</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a non-membrane spanning protein L-tyrosine = ADP + a non-membrane spanning protein L-tyrosine phosphate.</Detail>
      <Keyword>Non-membrane spanning protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004715</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester.</Detail>
      <Keyword>Phospholipid binding</Keyword>
      <Ontology_ID>GO:0005543</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).</Detail>
      <Keyword>Protein binding</Keyword>
      <Ontology_ID>GO:0005515</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>581</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>19</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>23</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>451</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>193</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>587</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>335</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Protein involved in adaptive immunity. Vertebrates can develop a broad and almost infinite repertoire of antigen-specific receptors, which allows vertebrates to recognize almost any potential pathogen or toxin and to mount antigen-specific responses to it. Two types of adaptive immunity systems have evolved in vertebrates in order to generate immune receptor diversity. The jawed vertebrates strategy uses the V(D)JC recombination to achieve combinatorial diversity of immunoglobulin-based B cell receptors and T cell receptors. The jawless vertebrate strategy uses the somatic rearrangements of variable leucine-rich cassettes in the variable lymphocyte receptors (VLRs). The hallmarks of an adaptive immune system is the production of antigen-specific recognition receptor by somatic gene rearrangement. The long life of some antigen-primed cytotoxic lymphocytes and plasma cells provide protective memory to prevent reinvasion.</Detail>
      <Keyword>Adaptive immunity</Keyword>
      <Ontology_ID>KW-1064</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory).</Detail>
      <Keyword>Adaptive immune response</Keyword>
      <Ontology_ID>GO:0002250</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in immunity, any immune system process that functions in the response of an organism to a potential internal or invasive threat. The vertebrate immune system is formed by the innate immune system (composed of phagocytes, complement, antimicrobial peptides, etc) and by the adaptive immune system which consists of T- and B-lymphocytes.</Detail>
      <Keyword>Immunity</Keyword>
      <Ontology_ID>KW-0391</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell.</Detail>
      <Keyword>Intracellular signal transduction</Keyword>
      <Ontology_ID>GO:0035556</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A defense response that is mediated by cells.</Detail>
      <Keyword>Cellular defense response</Keyword>
      <Ontology_ID>GO:0006968</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initiation of the activity of the inactive enzyme phospolipase C as the result of a series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>Activation of phospholipase C activity</Keyword>
      <Ontology_ID>GO:0007202</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell.</Detail>
      <Keyword>T cell receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0050852</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>180</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>565</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>296</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>512</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MNNFILLEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISIPCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNASKKPLPPTPEDNRRPLWEPEETVVIALYDYQTNDPQELALRRNEEYCLLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKSISRDKAEKLLLDTGKEGAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSIPLLINYHQHNGGGLVTRLRYPVCFGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHLGYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFMEHGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVSDFGMTRFVLDDQYTSSTGTKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFSEGKIPYENRSNSEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPEDRPAFSRLLRQLAEIAESGL</Protein_Seq>
    <DNA_Seq>TGCATTCTTTGCCCCAAAACTCTTTCCTTTGGTTGTGCTAAGAGGTGATGCCCAAGGTGCACCACCTTTCAAGAACTGGATCATGAACAACTTTATCCTCCTGGAAGAACAGCTCATCAAGAAATCCCAACAAAAGAGAAGAACTTCTCCCTCGAACTTTAAAGTCCGCTTCTTTGTGTTAACCAAAGCCAGCCTGGCATACTTTGAAGATCGTCATGGGAAGAAGCGCACGCTGAAGGGGTCCATTGAGCTCTCCCGAATCAAATGTGTTGAGATTGTGAAAAGTGACATCAGCATCCCATGCCACTATAAATACCCGTTTCAGGTGGTGCATGACAACTACCTCCTATATGTGTTTGCTCCAGATCGTGAGAGCCGGCAGCGCTGGGTGCTGGCCCTTAAAGAAGAAACGAGGAATAATAACAGTTTGGTGCCTAAATATCATCCTAATTTCTGGATGGATGGGAAGTGGAGGTGCTGTTCTCAGCTGGAGAAGCTTGCAACAGGCTGTGCCCAATATGATCCAACCAAGAATGCTTCAAAGAAGCCTCTTCCTCCTACTCCTGAAGACAACAGGCGACCACTTTGGGAACCTGAAGAAACTGTGGTCATTGCCTTATATGACTACCAAACCAATGATCCTCAGGAACTCGCACTGCGGCGCAACGAAGAGTACTGCCTGCTGGACAGTTCTGAGATTCACTGGTGGAGAGTCCAGGACAGGAATGGGCATGAAGGATATGTACCAAGCAGTTATCTGGTGGAAAAATCTCCAAATAATCTGGAAACCTATGAGTGGTACAATAAGAGTATCAGCCGAGACAAAGCTGAAAAACTTCTTTTGGACACAGGCAAAGAAGGAGCCTTCATGGTAAGGGATTCCAGGACTGCAGGAACATACACCGTGTCTGTTTTCACCAAGGCTGTTGTAAGTGAGAACAATCCCTGTATAAAGCATTATCACATCAAGGAAACAAATGACAATCCTAAGCGATACTATGTGGCTGAAAAGTATGTGTTCGATTCCATCCCTCTTCTCATCAACTATCACCAACATAATGGAGGAGGCCTGGTGACTCGACTCCGGTATCCAGTTTGTTTTGGGAGGCAGAAAGCCCCAGTTACAGCAGGGCTGAGATACGGGAAATGGGTGATCGACCCCTCAGAGCTCACTTTTGTGCAAGAGATTGGCAGTGGGCAATTTGGGTTGGTGCATCTGGGCTACTGGCTCAACAAGGACAAGGTGGCTATCAAAACCATTCGGGAAGGGGCTATGTCAGAAGAGGACTTCATAGAGGAGGCTGAAGTAATGATGAAACTCTCTCATCCCAAACTGGTGCAGCTGTATGGGGTGTGCCTGGAGCAGGCCCCCATCTGCCTGGTGTTTGAGTTCATGGAGCACGGCTGCCTGTCAGATTATCTACGCACCCAGCGGGGACTTTTTGCTGCAGAGACCCTGCTGGGCATGTGTCTGGATGTGTGTGAGGGCATGGCCTACCTGGAAGAGGCATGTGTCATCCACAGAGACTTGGCTGCCAGAAATTGTTTGGTGGGAGAAAACCAAGTCATCAAGGTGTCTGACTTTGGGATGACAAGGTTCGTTCTGGATGATCAGTACACCAGTTCCACAGGCACCAAATTCCCGGTGAAGTGGGCATCCCCAGAGGTTTTCTCTTTCAGTCGCTATAGCAGCAAGTCCGATGTGTGGTCATTTGGTGTGCTGATGTGGGAAGTTTTCAGTGAAGGCAAAATCCCGTATGAAAACCGAAGCAACTCAGAGGTGGTGGAAGACATCAGTACCGGATTTCGGTTGTACAAGCCCCGGCTGGCCTCCACACACGTCTACCAGATTATGAATCACTGCTGGAAAGAGAGACCAGAAGATCGGCCAGCCTTCTCCAGACTGCTGCGTCAACTGGCTGAAATTGCAGAATCAGGACTTTAGTAGAGACTGAGTACCAGGCCACGGGCTGCAGATCCTGAATGGAGGAAGGATATGTCCTCATTCCATAGAGCATTAGAAGCTGCCACCAGCCCAGGACCCTCCAGAGGCAGCCTGGCCTGTGGCATCAGTCCCTGAGTCACCATGGAAGCAGCATCCTGACCACAGCTGGCAGTCAAGCCACAGCTGGAGGGTCAGCCACCAAGCTGGGAGCTGAGCCAGAACAGGAGTGATGTCTCTGCCCTTCCTCTAGCCTCTTGTCACATGTGGTGCACAAACCTCAACCTGACAGCTTTCAGACAGCATTCTTGCACTTCTTAGCAACAGAGAGAGACATGAGTAAGACCCAGATTGCTATTTTTATTGTTATTTTTAACATGAATCTAAAGTTTATGGTTCCAGGGACTTTTTATTTGACCCAACAACACAGTATCCCAGGATATGGAGGCAAGGGGAACAAAGAGCATGAGTCTTTTTCCAAGAAAACTGGTGAGTTAAGTAAGATTAGAGTGAGTGTGCTCTGTTGCTGTGATGCTGTCAGCCACAGCTTCCTGCCGTAGAGAATGATAGAGCAGCTGCTCACACAGGAGGCCGGATATTCTGAGAAGCAGCTTTATGAGGTTTTACAGAGTATGCTGCTACCTCTCTCCTTGAAGGGAGCATGGCGAGACCCATTGGATGGATTGGGGTGAACAGTTCAGGTCCCATGCTTGGAGCATTGGGTATCTGATGTCTGCACCAGAACAAGAGAACCTCTGACGGTGGAGAACCATGTGGTGCAAGAAGAGATCTTAGGTCTCTTCTTTTATACCAAGCTCATCTTTTATACCAAGCTGTGCAGGTGACTATGCCTCCTCTTCTGCACAGAATGCTTCCACCAGCATCCTGAGAAGAAATGATTACTTCTGAAAAACATCCTTTTTTCCAGCCTCTGGGAATCAGCCCCCCCTCTCTGCACTATCCGATCCTCATCAACAGAGGGCAGCATTGTGTTGGTCAATGTTCCCTTGGCGAGCAATTGAAACTTGTTTAGGCCCTAGGGTTGAGCAATTTTAAGGTTGAGACTCCAAGTCTCCTAAAATTCTAGGAGAGAAATAAAGAGTCTGTTTTTGCTCAAACCATCAGGATGGAAACAGTCAGGCACTGACTGGGGTGCTTCCAAGAGGCATGAGAGTGCCTACTCTGGCTTGAGCACTTCTATATGCAAGGTGAATATGTACTGAGCTAGGAGACTTCCCTGCAAAATCTCTGTTCACCCTGGGTTCACATCCCCATGAGGTAATATTATTATTCCCATTTTACAAATAATGTAACTGAGGCTTTAAAAAGCCAAGACATCTGCCCAAAGTGATGGAACTAGAAAGTCTAGAGCTGGTATTCTAGCCCAAATCTGTCTGACCGCAATACACAGATTCTTTATTCCTATTCGACACTGGCTTCTACTGAAAATGAAACGGATTGCAGAGGGAATAAATACAAAGATGGAAAGCCAGTAAAGAAGTCAGTATAGAACCACTAGCGAATAGTGTTGCTCTGGCACAGACCACTGTGGTTGATGGCATGGCCCTCCAACTTGGAATAGGATTTTCCTTTTCCTATTCTGTATCCTTACCTTGGTCATGTTAATGACTTTGGAGTTATTCAGTTAATGACCCTTTAATTCTCACAACCAACCAGTCATGTTGCTTGAAGCCATTTATAGACGAGCTTCAAAGCAACTTTAAAAGATTCTTCTGTAGAAGTATGAGTTCTTCCTTTAATTATCATTCCAACTTTCAGCTGTAGTCTTCTTGAACACTTCATGAGGAGGGACATTCCCTGATATAAGAGAGGATGGTGTTGCAATTGGCTCTTTCTAAATCATGTGACGTTTTGACTGGCTTGAGATTCAGATGCATAATTTTTAATTATAATTATTGTGAAGTGGAGAGCCTCAAGATAAAACTCTGTCATTCAGAAGATGATTTTACTCAGCTTATCCAAAATTATCTCTGTTTACTTTTTAGAATTTTGTACATTATCTTTTGGGATCCTTAATTAGAGATGATTTCTGGAACATTCAGTCTAGAAAGAAAACATTGGAATTGACTGATCTCTGTGGTTTGGTTTAGAAAATTCCCCTGTGCATGGTATTACCTTTTTCAAGCTCAGATTCATCTAATCCTCAACTGTACATGTGTACATTCTTCACCTCCTGGTGCCCTATCCCGCAAAATGGGCTTCCTGCCTGGTTTTTCTCTTCTCACATTTTTTAAATGGTCCCCTGTGTTTGTAGAGAACTCCCTTATACAGAGTTTTGGTTCTAGTTTTATTTCGTAGATTTTGCATTTTGTACCTTTTGAGACTATGTATTTATATTTGGATCAGATGCATATTTATTAATGTACAGTCACTGCTAGTGTTCAAAATAAAAATGTTACAAAT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>T-lymphocytes</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Natural killer cells</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ITK</Gene_Name>
    <Gene_Alias>EMT; LYK</Gene_Alias>
    <Gene_ID>3702</Gene_ID>
    <Genbank_ACCN>NM_005546</Genbank_ACCN>
    <Protein_ACCN>NP_005537</Protein_ACCN>
    <HGNC_ID>6171</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3702</Gene_URL>
    <UCSC_ID>uc003lwo.1</UCSC_ID>
    <EMBL_ID>ENSG00000113263</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P48023</Uniprot_ID>
      <Gene_Name>FASLG</Gene_Name>
      <EBI_ID>EBI-495538</EBI_ID>
      <PPI_EBI_URL>EBI-968552,EBI-495538</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Peripheral T-Cell Lymphoma</Disease_Name>
      <Disease_Detail>Peripheral T-Cell Lymphoma</Disease_Detail>
      <Disease_DB>PRP036</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peripheral_t_cell_lymphoma?search=ITK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphoproliferative Syndrome 1</Disease_Name>
      <Disease_Detail>Lymphoproliferative Syndrome</Disease_Detail>
      <Disease_DB>LYM106</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphoproliferative_syndrome_1?search=ITK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphoproliferative Syndrome, Ebv-Associated, Autosomal, 1</Disease_Name>
      <Disease_Detail>Lymphoproliferative Syndrome</Disease_Detail>
      <Disease_DB>LYM054</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphoproliferative_syndrome_ebv_associated_autosomal_1?search=ITK#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <Allosteric_Pathway>
    <Pathway>W356, M411, M410, L421, F501, H480, D540</Pathway>
    <Method>Structural analysis, mutations.</Method>
    <Verified__Residue>W356, M411, M410, L421, F501, H480, D540</Verified__Residue>
    <PubMed_Title>Joseph RE, et al. J Mol Biol. 2010,403(2):231, 242.</PubMed_Title>
    <PubMed_ID>20826165</PubMed_ID>
    <is__ref__img>No</is__ref__img>
    <is__display>Yes</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of ITK inhibitor complex</PDB_Title>
      <PDB_ID>3QGY</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QGY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors</PubMed_Title>
      <Author>Charrier, J.D., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:2341-2350</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21391610?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the phosphorylated Interleukin-2 tyrosine kinase catalytic domain</PDB_Title>
      <PDB_ID>1SM2</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SM2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.</PubMed_Title>
      <Author>Brown, K., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:18727-18732</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14766749?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 1 [4-(carbamoylamino)-1-(naphthalen-1-yl)-1H-pyrazole-3-carboxamide]</PDB_Title>
      <PDB_ID>4M0Y</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M0Y</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820002</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN</PDB_Title>
      <PDB_ID>1SNX</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SNX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.</PubMed_Title>
      <Author>Brown, K., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:18727-18732</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14766749?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of ITK complexed with inhibitor BMS-509744</PDB_Title>
      <PDB_ID>3MJ2</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3MJ2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.</PubMed_Title>
      <Author>Kutach, A.K., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2010)76:154-163</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20545945?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the BTK motif of tyrosine-protein kinase ITK from human</PDB_Title>
      <PDB_ID>2E6I</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2E6I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the BTK motif of tyrosine-protein kinase ITK from human</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 5 {4-(carbamoylamino)-1-(7-methoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide}</PDB_Title>
      <PDB_ID>4M0Z</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M0Z</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820001</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of ITK complexed with sunitinib</PDB_Title>
      <PDB_ID>3MIY</PDB_ID>
      <Resolution>1.67</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3MIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.</PubMed_Title>
      <Author>Kutach, A.K., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2010)76:154-163</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20545945?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of ITK kinase bound to an inhibitor</PDB_Title>
      <PDB_ID>3QGW</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QGW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors</PubMed_Title>
      <Author>Charrier, J.D., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:2341-2350</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21391610?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide]</PDB_Title>
      <PDB_ID>4M14</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M14</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820004</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 8 [4-(carbamoylamino)-1-(7-propoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]</PDB_Title>
      <PDB_ID>4M13</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M13</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820003</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 542</PDB_Title>
      <PDB_ID>3V5L</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V5L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3296-3300</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22464456?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN</PDB_Title>
      <PDB_ID>1SNU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SNU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.</PubMed_Title>
      <Author>Brown, K., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:18727-18732</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14766749?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of ITK complexed with inhibitor RO5191614</PDB_Title>
      <PDB_ID>3MJ1</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3MJ1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.</PubMed_Title>
      <Author>Kutach, A.K., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2010)76:154-163</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20545945?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the SH3 domain of human Tyrosine-protein kinase ITK/TSK</PDB_Title>
      <PDB_ID>2YUQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YUQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the SH3 domain of human Tyrosine-protein kinase ITK/TSK</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide] and ADP</PDB_Title>
      <PDB_ID>4M15</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M15</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820004</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of BTK mutant (F435T,K596R) complexed with Imidazo[1,5-a]quinoxaline</PDB_Title>
      <PDB_ID>3T9T</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3T9T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.</PubMed_Title>
      <Author>Kim, K.H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:6258-6263</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21958547?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 090</PDB_Title>
      <PDB_ID>3V5J</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V5J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3296-3300</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22464456?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ITK in complex with compound 7 [4-(carbamoylamino)-1-(7-ethoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]</PDB_Title>
      <PDB_ID>4M12</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4M12</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD08820006</ASD_Ligand>
      <PubMed_Title>Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.</PubMed_Title>
      <Author>Han, S., et al.</Author>
      <Journal>Biochem.J.(2014)460:211-222</Journal>
      <PubMed_ID>24593284</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 469</PDB_Title>
      <PDB_ID>3V8W</PDB_ID>
      <Resolution>2.27</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V8W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3296-3300</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22464456?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 477</PDB_Title>
      <PDB_ID>3V8T</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V8T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.</PubMed_Title>
      <Author>McLean, L.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3296-3300</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22464456?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04660</Pathway_ID>
      <Pathway_Title>T cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04670</Pathway_ID>
      <Pathway_Title>Leukocyte transendothelial migration</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04062</Pathway_ID>
      <Pathway_Title>Chemokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.ga.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1sm2</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.2</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/2.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD08820001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08820002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08820003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08820004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD08820006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>